The influence of SLC22A1 rs622342 and ABCC8 rs757110 genetic variants on the efficacy of metformin and glimepiride combination therapy in Egyptian patients with type 2 diabetes

Figures & data

Figure 1. Patients inclusion and exclusion criteria.

Table 1. Patients characteristics.

	Responders, n = 93 (73.2%)	Non-responders, n = 34 (26.8%)	p-value^a
Gender
Male (25.2%)	27	5	0.100^b
Female (74.8%)	66	29
Age (years)	51.2 (±7.7)	49.6 (±9.2)	0.327
Treatment duration (years)	2.3 (±1.1)	2.6 (±1.2)	0.239
Metformin daily dose (mg/day)	1,154.2 (±483)	1,220.6 (±521)	0.501
Glimepiride daily dose (mg/day)	4.5 (±1.8)	4.5 (±1.7)	0.895
FBGL (mg/dL)	123.6 (±21.4)	197.3 (±35.7)	<0.001*
HbA1C (%)	6.0 (±0.54)	8.3 (±1.09)	<0.001*
eAG (mg/dL)^c	123.7 (±13.8)	192.9 (±28.7)	<0.001*
BMI (Kg/m^2)	38.9 (±8.4)	39 (±7.2)	0.990
Systole (mmHg)	130.2 (±23.7)	124.3 (±38.2)
Diastole (mmHg)	84.1 (±9.4)	86.2 (±8.3)
Concomitant medication
Lisinopril	35	16
Aspirin	24	9
Thioctic acid	6	2

Abbreviations. BMI, body mass index; eAG, estimated average glucose; FBGL, fasting blood glucose level; HbA1C, glycated hemoglobin.

Mean ± standard deviation was used to express continuous variables.

^a Unpaired Student t-test was used for continuous variables.

^b Chi-squared test was used.

^c Calculated using the following equation: eAG = 28.7 × HbA1C – 46.7.

*Statistically significant at p ≤ 0.05 level.

Table 2. SLC22A1 rs622342 and ABCC8 rs757110 variants distribution among study groups.

	Genotype	Total sample (n = 127), n (%)	Responders (n = 93), n (%)	Non-responders (n = 34), n (%)	MAF	p-value^a
Rs622342 A>C	AA	85 (66.9)	67 (72)	18 (52.9)	0.189	0.043*
	AC	36 (28.3)	26 (28)^b	16 (47.1)^b
	CC	6 (4.8)
Rs757110 A>C	AA	67 (52.8)	47 (50.5)	20 (58.8)	0.271	0.408
	AC	51 (40.2)	46 (49.5)^b	14 (41.2)^b
	CC	9 (7)

Abbreviations. MAF, minor allele frequency.

^a Chi-square test was used to test the distribution of each genetic variant (AA alleles carriers and C allele carriers) between responder and non-responder groups.

^b Represents C-allele carriers (AA and AC).

*Statistically significant at p ≤ 0.05 level.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.